PMID- 28849168
OWN - NLM
STAT- MEDLINE
DCOM- 20180608
LR  - 20181113
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Print)
IS  - 1791-2997 (Linking)
VI  - 16
IP  - 4
DP  - 2017 Oct
TI  - MicroRNA‑503 serves an oncogenic role in laryngeal squamous cell carcinoma via 
      targeting programmed cell death protein 4.
PG  - 5249-5256
LID - 10.3892/mmr.2017.7278 [doi]
AB  - Laryngeal squamous cell carcinoma (LSCC), the most common form of laryngeal 
      carcinoma, is an aggressive malignancy that demonstrates the second highest rate 
      of morbidity of all head and neck squamous cell carcinomas. The abnormal 
      expression of microRNAs (miRs) has been demonstrated in a number of types of 
      human cancer, and they have been demonstrated to be oncogenes or tumour 
      suppressor genes. miR‑503 has been studied in various types of human cancer; 
      however, the expression level, roles and underlying mechanisms in LSCC remain 
      unknown. In the present study, it was demonstrated that miR‑503 was significantly 
      upregulated in LSCC tissues and cell lines. The level of miR‑503 in LSCC tissues 
      was correlated with thyroid cartilage invasion, lymph node metastasis, and 
      tumour, node and metastasis stage. In addition, down‑regulation of miR‑503 
      inhibited cell proliferation and invasion in LSCC. Programmed cell death protein 
      4 (PDCD4) was identified to be a direct target gene of miR‑503. PDCD4 
      overexpression could mimic the roles of miR‑503 underexpression in LSCC. 
      Furthermore, PDCD4 was down‑regulated in LSCC tissues and this correlated with 
      the miR‑503 expression level. In conclusion, these results suggested that miR‑503 
      promotes tumour growth and invasion by directly targeting PDCD4. The 
      identification of the miR‑503/PDCD4 axis may provide novel targets for LSCC 
      treatment and improve prognosis.
FAU - Shuang, Yu
AU  - Shuang Y
AD  - Department of Otorhinolaryngology and Maxillofacial Oncology, Tianjin Medical 
      University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and 
      Therapy, Tianjin Cancer Institute, National Clinical Research Center of Cancer, 
      Tianjin 300060, P.R. China.
FAU - Zhou, Xuan
AU  - Zhou X
AD  - Department of Otorhinolaryngology and Maxillofacial Oncology, Tianjin Medical 
      University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and 
      Therapy, Tianjin Cancer Institute, National Clinical Research Center of Cancer, 
      Tianjin 300060, P.R. China.
FAU - Li, Chao
AU  - Li C
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, The Second Hospital of 
      Tianjin Medical University, Tianjin 300211, P.R. China.
FAU - Huang, Yongwang
AU  - Huang Y
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, The Second Hospital of 
      Tianjin Medical University, Tianjin 300211, P.R. China.
FAU - Zhang, Lun
AU  - Zhang L
AD  - Department of Otorhinolaryngology and Maxillofacial Oncology, Tianjin Medical 
      University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and 
      Therapy, Tianjin Cancer Institute, National Clinical Research Center of Cancer, 
      Tianjin 300060, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20170817
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (3' Untranslated Regions)
RN  - 0 (Apoptosis Regulatory Proteins)
RN  - 0 (MIRN503 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (PDCD4 protein, human)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - 3' Untranslated Regions/genetics
MH  - Apoptosis Regulatory Proteins/*genetics/metabolism
MH  - Base Sequence
MH  - Carcinoma, Squamous Cell/*genetics/*pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Down-Regulation/genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - HEK293 Cells
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics/*pathology
MH  - Male
MH  - MicroRNAs/genetics/*metabolism
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - RNA-Binding Proteins/*genetics/metabolism
MH  - Up-Regulation/genetics
PMC - PMC5647079
EDAT- 2017/08/30 06:00
MHDA- 2018/06/09 06:00
PMCR- 2017/08/17
CRDT- 2017/08/30 06:00
PHST- 2016/09/21 00:00 [received]
PHST- 2017/06/22 00:00 [accepted]
PHST- 2017/08/30 06:00 [pubmed]
PHST- 2018/06/09 06:00 [medline]
PHST- 2017/08/30 06:00 [entrez]
PHST- 2017/08/17 00:00 [pmc-release]
AID - mmr-16-04-5249 [pii]
AID - 10.3892/mmr.2017.7278 [doi]
PST - ppublish
SO  - Mol Med Rep. 2017 Oct;16(4):5249-5256. doi: 10.3892/mmr.2017.7278. Epub 2017 Aug 
      17.